Eliem Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“In preclinical studies, ETX-155 showed favorable pharmacokinetic properties and potent activity across several animal models of CNS diseases. Based on these studies, we believe ETX-155 is a promising investigational therapy for treatment of psychiatric mood disorders and focal onset seizures.” (Page 119) Read the full document
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company. The Company focuses on developing therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems.
Company Website: https://eliemtx.com